Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study
Authors' conclusion
The safety and effectiveness of TCZ-SC is maintained over 2 years during routine clinical care.
Study context
- Population
- Adults with active rheumatoid arthritis (RA) initiating TCZ-SC in routine clinical care, 114 centres in Germany, May 2014–July 2018 (mean age 57.3 [SD 12.5] years; mean DAS28-ESR 4.9 [SD 1.3])
- Participants
- 1,300 adults114 centres
- Outcome
- Proportion achieving DAS28-ESR <2.6
- Follow-up
- Week 104
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
DAS28-ESR <2.6
Patients achieving DAS28-ESR <2.6
58.7%
365/622
Observational data: associations, not effects.
Further findings
Individual DAS28-dcrit response (improvement of ≥1.8 from baseline) · week 104
- Patients with an individual DAS28-dcrit response
- 64.0%
CDAI remission (≤2.8) · week 104
- Patients achieving CDAI remission
- 31.4% (241/767)
Safety
- Injection reactions were rare and no new safety signals occurred
Original publication
Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study. Clin Exp Rheumatol. Published 21 June 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →